⚠️ Research Use Only. The following is provided for scientific and educational purposes only. These compounds are not approved for human or veterinary use.
Overview
Two of the most researched peptide compounds currently available in Australia are Retatrutide (LY3437943) and Tirzepatide. Both target GLP-1 receptors, but they differ significantly in their receptor profiles, mechanisms, and research applications. This comparison examines the key structural and functional differences researchers should understand before sourcing either compound.
Receptor Profile — The Core Difference
The most fundamental distinction between these two compounds is their receptor targeting:
- Tirzepatide is a dual GIP/GLP-1 receptor agonist — it simultaneously activates glucose-dependent insulinotropic polypeptide (GIP) receptors and glucagon-like peptide-1 (GLP-1) receptors.
- Retatrutide is a triple GLP-1/GIP/glucagon receptor agonist — it adds glucagon receptor agonism to the dual profile of Tirzepatide, making it the only triple agonist peptide currently available for research in Australia.
This additional glucagon receptor activity is significant in research settings. Glucagon receptors play a key role in hepatic glucose production and energy expenditure, adding a third pathway to Retatrutide's research profile that Tirzepatide does not engage.
Molecular Structure
Both compounds are synthetic peptides derived from GIP sequence scaffolds, but their structural modifications differ considerably:
- Tirzepatide is a 39-amino acid peptide with a C20 fatty diacid moiety attached via a gamma-glutamic acid linker, enabling albumin binding and extended half-life in research models.
- Retatrutide is also a 39-amino acid peptide, engineered to balance agonist activity across three receptors simultaneously — a significantly more complex pharmacological challenge than dual agonism.
Research Applications
Given their different receptor profiles, the two compounds are used in distinct research contexts:
- Tirzepatide research tends to focus on GIP and GLP-1 pathway interactions, insulin secretion mechanisms, beta cell function, and metabolic regulation. It is one of the most extensively studied dual agonists in the research literature.
- Retatrutide research is more commonly seen in studies examining the combined effects of GLP-1, GIP, and glucagon receptor co-activation, particularly in contexts related to hepatic metabolism, energy homeostasis, and adipose tissue regulation.
Purity and Storage Considerations
For researchers sourcing either compound, purity verification is critical. At Aussie Peptide Hub, both Retatrutide and Tirzepatide are supplied at ≥99.0% purity, verified by RP-HPLC analysis with a Certificate of Analysis available for each batch.
Both compounds should be stored dry at 2–8°C prior to reconstitution. Once reconstituted with bacteriostatic water, refrigerate immediately and use within 6 weeks. Avoid repeated freeze-thaw cycles as this can degrade peptide integrity.
Sourcing in Australia
Researchers looking to buy Retatrutide in Australia or buy Tirzepatide in Australia should prioritise suppliers who provide third-party verified COA documentation, GMP-compliant manufacturing, and transparent purity data. Both compounds are available at Aussie Peptide Hub with fast domestic dispatch — most orders ship within 24–48 hours.
Summary Comparison
| Feature | Tirzepatide | Retatrutide |
|---|---|---|
| Receptor targets | GLP-1, GIP | GLP-1, GIP, Glucagon |
| Agonist type | Dual | Triple |
| Amino acids | 39 | 39 |
| Purity (APH) | ≥99.0% | ≥99.0% |
| Storage | 2–8°C dry | 2–8°C dry |
| Available in Australia | Yes | Yes |
Disclaimer
This article is intended for educational and research purposes only. Retatrutide and Tirzepatide are supplied by Aussie Peptide Hub strictly for in vitro laboratory research and scientific investigation. These compounds are not approved for human or veterinary use. No therapeutic claims are made. Researchers are responsible for compliance with all applicable laws and regulations in their jurisdiction.